These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36467087)

  • 41. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
    Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
    Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database.
    Zhao H; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
    Front Pharmacol; 2023; 14():1110575. PubMed ID: 36865915
    [No Abstract]   [Full Text] [Related]  

  • 47. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 50. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
    Ji HH; Tang XW; Dong Z; Song L; Jia YT
    Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
    Shu Y; Ding Y; Liu L; Zhang Q
    CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 53. Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System.
    Yang H; Yu X; An Z
    Front Oncol; 2021; 11():801199. PubMed ID: 35127510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system.
    Wei C; Zhang J; Yin W; Jiang A; Liu Y; Wu B
    Expert Opin Drug Saf; 2023; 22(6):509-515. PubMed ID: 36373417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
    Cui C; Deng L; Wang W; Ren X; Wang Y; Cui W
    Front Oncol; 2022; 12():941079. PubMed ID: 36059699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.